New Edition of Cancer Care’s Helping Hand Available

Publication
Article
OncologyONCOLOGY Vol 16 No 8
Volume 16
Issue 8

Cancer Care has published the fourth edition of its handbook-A Helping Hand: The Resource Guide for People With Cancer. The 148-page booklet contains listings and descriptions of organizations that offer a wide variety of services, support, and information for people with cancer. In general, the booklet shows cancer patients what types of help are available to them and where they can find it, both nationally and regionally. Listings include cancer centers, commercial services that offer products of particular interest to people with cancer (such as wigs and prostheses), state pharmaceutical assistance programs, pharmaceutical manufacturers’ indigent drug programs, and useful tips on what to ask when contacting such services.

Cancer Care has published the fourth edition of itshandbook—A Helping Hand: The Resource Guide for People With Cancer. The148-page booklet contains listings and descriptions of organizations that offera wide variety of services, support, and information for people with cancer. Ingeneral, the booklet shows cancer patients what types of help are available tothem and where they can find it, both nationally and regionally. Listingsinclude cancer centers, commercial services that offer products of particularinterest to people with cancer (such as wigs and prostheses), statepharmaceutical assistance programs, pharmaceutical manufacturers’ indigentdrug programs, and useful tips on what to ask when contacting such services.

The booklet can be ordered by calling 1-800-813-4673 and is available as asearchable database on Cancer Care’s website, www.cancercare.org.

Recent Videos
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.